Literature DB >> 16367922

Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ.

Kazuyuki Matsushita1, Toshinao Takenouchi, Hideaki Shimada, Takeshi Tomonaga, Hideki Hayashi, Ayumi Shioya, Aki Komatsu, Hisahiro Matsubara, Takenori Ochiai.   

Abstract

Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients, although the precise mechanism is controversial. From an immunological point of view, HLA-DR antigen, induced by interferon (IFN)-gamma, is required for tumor-associated antigen recognition by CD4(+) T cells. For instance, as reported previously, the expression of HLA-DR antigen in normal colorectal epithelium immediately adjacent to cancer coincided significantly with the existence of IFN-gamma mRNA in the tissue. From another aspect, IFN-gamma has been revealed to suppress c-myc expression in vivo through a stat1-dependent mechanism, which is important for cell growth, cell cycle and chromosome instability. In the present study, strong HLA-DR-positive expression on cancer cells was significantly related to better prognosis for colorectal cancer patients. High IFN-gamma mRNA expression in situ indicated significantly less activation of c-myc mRNA expression. Further, HLA-DR antigen expression in cancer cells, as well as Dukes stages, was an independent factor for better long-term survival by multivariate analysis. Taken together, IFN-gamma, which induces HLA-DR antigens on the cell surface, also suppresses c-myc expression in situ, and is a possible non-immunological mechanism involved in the better long-term survival of colorectal cancer patients. (Cancer Sci 2006; 97: 57- 63).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16367922     DOI: 10.1111/j.1349-7006.2006.00137.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  25 in total

1.  Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Authors:  Kazuyuki Matsushita; Hideaki Shimada; Yasuji Ueda; Makoto Inoue; Mamoru Hasegawa; Takeshi Tomonaga; Hisahiro Matsubara; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

3.  Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc.

Authors:  Feng-Hou Gao; Xiao-Hui Hu; Wei Li; Hua Liu; Yan-Jie Zhang; Zhu-Ying Guo; Mang-Hua Xu; Shi-Ting Wang; Bin Jiang; Feng Liu; Ying-Zheng Zhao; Yong Fang; Fang-Yuan Chen; Ying-Li Wu
Journal:  BMC Cancer       Date:  2010-11-06       Impact factor: 4.430

4.  Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.

Authors:  Michael J Callahan; Zoltan Nagymanyoki; Tomas Bonome; Michael E Johnson; Babak Litkouhi; Elizabeth H Sullivan; Michelle S Hirsch; Ursula A Matulonis; Joyce Liu; Michael J Birrer; Ross S Berkowitz; Samuel C Mok
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

5.  Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.

Authors:  Kazuyuki Matsushita; Mai Tamura; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; David Levens; Liusheng He; Juhong Liu; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2013-04-17       Impact factor: 5.852

6.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

Review 7.  Clinical Use of Interferon-gamma.

Authors:  Catriona H T Miller; Stephen G Maher; Howard A Young
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

8.  The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

Authors:  Tyler R McCaw; Mei Li; Dmytro Starenki; Sara J Cooper; Mingyong Liu; Selene Meza-Perez; Rebecca C Arend; Donald J Buchsbaum; Andres Forero; Troy D Randall
Journal:  Cancer Immunol Immunother       Date:  2018-10-17       Impact factor: 6.968

Review 9.  Cell surface markers in colorectal cancer prognosis.

Authors:  Larissa Belov; Jerry Zhou; Richard I Christopherson
Journal:  Int J Mol Sci       Date:  2010-12-28       Impact factor: 5.923

10.  Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers.

Authors:  J Lee; L Li; N Gretz; J Gebert; S Dihlmann
Journal:  Oncogene       Date:  2011-08-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.